(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 July 2012 (26.07.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/099973 A2

(51) International Patent Classification:
A61K 48/00 (2006.01)

(21) International Application Number:
PCT/US2012/021738

(22) International Filing Date:
18 January 2012 (18.01.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/433,731 18 January 2011 (18.01.2011) US

(71) Applicant *(for all designated States except US)*: **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; Center for Technology Transfer, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6283 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **POWELL, Daniel, J.** [US/US]; 36 Aberdale Road, Bala Cynwyd, PA 19004 (US). **COUKOS, George** [IT/US]; 465 Clothier Road, Wynnewood, PA 19096 (US). **JUNE, Carl, H.** [US/US]; 409 Baird Road, Merion Station, PA 19066 (US).

(74) Agents: **NGUYEN, Quang, D.** et al.; Riverside Law, LLP, 300 Four Falls Corporate Center, Suite 710, 300 Conshohocken State Road, West Conshohocken, PA 19428 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR TREATING CANCER

(57) Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having a-folate receptor (FRα) binding domain and 4- IBB (CD137) costimulatory domain to treat ovarian cancer.




Figure 1

WO 2012/099973 A2

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*